GR3018318T3 - Pharmaceutical agents. - Google Patents

Pharmaceutical agents.

Info

Publication number
GR3018318T3
GR3018318T3 GR950403190T GR950403190T GR3018318T3 GR 3018318 T3 GR3018318 T3 GR 3018318T3 GR 950403190 T GR950403190 T GR 950403190T GR 950403190 T GR950403190 T GR 950403190T GR 3018318 T3 GR3018318 T3 GR 3018318T3
Authority
GR
Greece
Prior art keywords
pharmaceutical agents
pharmaceutical
agents
Prior art date
Application number
GR950403190T
Other languages
Greek (el)
English (en)
Inventor
Robert Joseph Timko
Arlene Clements
Randy John Bradway
James Joseph Holohan
Ieuan John Edwards
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26298105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3018318(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB909027014A external-priority patent/GB9027014D0/en
Priority claimed from GB919115107A external-priority patent/GB9115107D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of GR3018318T3 publication Critical patent/GR3018318T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GR950403190T 1990-12-12 1995-12-07 Pharmaceutical agents. GR3018318T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909027014A GB9027014D0 (en) 1990-12-12 1990-12-12 Pharmaceutical agents
GB919115107A GB9115107D0 (en) 1991-07-12 1991-07-12 Pharmaceutical agents

Publications (1)

Publication Number Publication Date
GR3018318T3 true GR3018318T3 (en) 1996-03-31

Family

ID=26298105

Family Applications (1)

Application Number Title Priority Date Filing Date
GR950403190T GR3018318T3 (en) 1990-12-12 1995-12-07 Pharmaceutical agents.

Country Status (30)

Country Link
US (6) US5319097A (enExample)
EP (1) EP0490648B1 (enExample)
JP (1) JP2585495B2 (enExample)
KR (2) KR0183027B1 (enExample)
CN (2) CN1043405C (enExample)
AP (1) AP285A (enExample)
AT (1) ATE131048T1 (enExample)
AU (1) AU656157B2 (enExample)
BE (1) BE1004229A5 (enExample)
CA (2) CA2319308C (enExample)
CZ (1) CZ283181B6 (enExample)
DE (2) DE4140858A1 (enExample)
DK (1) DK0490648T3 (enExample)
ES (1) ES2079589T3 (enExample)
FI (1) FI101193B1 (enExample)
FR (1) FR2670488B1 (enExample)
GB (2) GB2280606B (enExample)
GR (1) GR3018318T3 (enExample)
HK (2) HK81597A (enExample)
HU (2) HU213211B (enExample)
IE (1) IE75348B1 (enExample)
IL (1) IL100091A (enExample)
IT (1) IT1256282B (enExample)
MX (1) MX9102473A (enExample)
MY (1) MY106315A (enExample)
NZ (1) NZ240939A (enExample)
PH (1) PH30928A (enExample)
RU (1) RU2106140C1 (enExample)
SK (2) SK279813B6 (enExample)
TW (1) TW276181B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
GB9119001D0 (en) * 1991-09-05 1991-10-23 Ici Plc Pharmaceutical agents
GR1001368B (el) * 1992-10-08 1993-10-29 Ici Plc Φαρμακευτικοί φορείς.
DE4235133A1 (de) * 1992-10-19 1994-04-21 Bayer Ag Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid
DE9410461U1 (de) * 1994-07-01 1994-09-22 Merck Patent Gmbh, 64293 Darmstadt Mittel für die Röntgenfluoreszenzanalyse
US6279736B1 (en) 1995-04-19 2001-08-28 Capitol Specialty Plastics, Inc. Barrier pack having an absorbing agent applied to the interior of the pack
IN182496B (enExample) * 1996-02-20 1999-04-17 Reddy Research Foundation
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
GB9723985D0 (en) 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
GB9726735D0 (en) * 1997-12-18 1998-02-18 Zeneca Ltd Pharmaceutical compositions
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6224907B1 (en) * 1998-03-06 2001-05-01 Alza Corporation Anti-asthma therapy
KR100283682B1 (ko) * 1998-07-14 2001-03-02 조정래 열풍건조장치
US6253463B1 (en) 1999-04-26 2001-07-03 Niro A/S Method of spray drying
IN191496B (enExample) 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
KR20020032611A (ko) * 1999-09-20 2002-05-03 스톤 스티븐 에프. 약물의 다형성 전환을 경감시키기 위한 공정
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate
IL139243A0 (en) * 2000-10-24 2001-11-25 Internat Specialty Products Is Ethanolate of zafirlukast, process for manufacture and pharmaceutical compositions thereof
IL140096A0 (en) * 2000-12-05 2002-02-10 Internat Specialty Products Is Process for preparation of zafirlukast
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
ME00145B (me) 2001-01-26 2010-10-10 Merck Sharp & Dohme Upotreba supstituisanih jedinjenja azetidinona za lečenje sitosterolemije
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
US20030109525A1 (en) * 2001-07-10 2003-06-12 Pharmacia & Upjohn Company Crystalline thiazine oxazolidinones
UA76483C2 (en) 2001-08-15 2006-08-15 Upjohn Co Crystalline form of malic acid salt of n-|2-(diethylamino)ethyl|-5-|(5-fluoro -2--oxo-3n-indol-3-ylidene)methyl]-2,4- dimelhyl-1n-pyrrole-3-carboxamide (variants), a method for preparing and compositions thereof
ATE345793T1 (de) * 2001-09-21 2006-12-15 Schering Corp Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
EP1562582A1 (en) 2002-11-06 2005-08-17 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
WO2004081003A1 (en) * 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
EP1601668B1 (en) 2003-03-07 2008-08-27 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
MY142017A (en) * 2004-03-19 2010-08-16 Nestec Sa Composition comprising all essential nutrients of a fruit or a plant material with increased stability and bioavailability and process of forming the same
ITMI20041032A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
CA2598288A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
US20070197467A1 (en) * 2006-02-06 2007-08-23 Srinivasulu Rangineni Zafirlukast compositions
US20090012146A1 (en) * 2007-07-02 2009-01-08 Giridhar Reddy Buggana Solubility-enhanced pharmaceutical compositions comprising zafirlukast
US20090191183A1 (en) * 2007-07-30 2009-07-30 Auspex Pharmaceuticals, Inc. Substituted indoles
US20090149662A1 (en) * 2007-12-05 2009-06-11 Raghupathi Reddy Anumula Processes for preparing zafirlukast
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
JP2017503814A (ja) 2014-01-22 2017-02-02 タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ 部分的コントロール状態の重症喘息またはコントロール不良状態の重症喘息のｐｄｅ４インヒビターを用いた（およびロイコトリエン調節薬と組み合わせて用いた）治療
PT109030B (pt) 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste
WO2018140858A1 (en) 2017-01-30 2018-08-02 Western New England University Thiol isomerases inhibitors and use thereof
US10752585B2 (en) 2017-12-28 2020-08-25 Council Of Scientific & Industrial Research Process for the preparation of Zafirlukast and analogs thereof
JP2024521736A (ja) 2021-05-19 2024-06-04 クエルシス ファーマ エージー 筋萎縮性側索硬化症の治療に使用するためのケルセチン含有組成物
WO2023214391A1 (en) 2022-05-06 2023-11-09 Quercis Pharma AG Method for treating cancers and neurological diseases using quercetin-containing compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
GB9027018D0 (en) * 1990-12-12 1991-01-30 Ici Plc Heterocyclic compounds
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation

Also Published As

Publication number Publication date
AP9100340A0 (en) 1992-01-31
NZ240939A (en) 1994-05-26
CS375691A3 (en) 1992-06-17
PH30928A (en) 1997-12-23
JP2585495B2 (ja) 1997-02-26
CA2319308C (en) 2001-08-21
CN1243827A (zh) 2000-02-09
GB2251791A (en) 1992-07-22
US5482963A (en) 1996-01-09
IL100091A (en) 1998-08-16
IE914310A1 (en) 1992-06-17
GB9418154D0 (en) 1994-10-26
US5993859A (en) 1999-11-30
ITMI913324A1 (it) 1993-06-11
IL100091A0 (en) 1992-08-18
BE1004229A5 (fr) 1992-10-13
TW276181B (enExample) 1996-05-21
FI101193B (fi) 1998-05-15
FI101193B1 (fi) 1998-05-15
HU913865D0 (en) 1992-02-28
JPH04266824A (ja) 1992-09-22
AU8899491A (en) 1992-06-18
CA2056066C (en) 2002-04-02
KR0183027B1 (ko) 1999-05-01
EP0490648A1 (en) 1992-06-17
MY106315A (en) 1995-04-29
ATE131048T1 (de) 1995-12-15
ITMI913324A0 (it) 1991-12-11
DE69115229T2 (de) 1996-05-09
US5504216A (en) 1996-04-02
AP285A (en) 1993-09-23
US5612367A (en) 1997-03-18
CA2056066A1 (en) 1992-06-13
AU656157B2 (en) 1995-01-27
ES2079589T3 (es) 1996-01-16
GB9126354D0 (en) 1992-02-12
HU213211B (en) 1997-03-28
MX9102473A (es) 1992-06-01
HUT61281A (en) 1992-12-28
FR2670488B1 (fr) 1994-01-28
RU2106140C1 (ru) 1998-03-10
CN1043405C (zh) 1999-05-19
HU211126A9 (en) 1995-10-30
CZ283181B6 (cs) 1998-01-14
IE75348B1 (en) 1997-08-27
GB2280606B (en) 1995-05-17
CN1062291A (zh) 1992-07-01
KR920011493A (ko) 1992-07-24
FI915826A0 (fi) 1991-12-11
US6143775A (en) 2000-11-07
KR970005014A (ko) 1997-01-29
DK0490648T3 (da) 1996-05-06
FR2670488A1 (fr) 1992-06-19
GB2251791B (en) 1995-05-17
SK279814B6 (sk) 1999-04-13
HK81597A (en) 1997-06-27
DE69115229D1 (de) 1996-01-18
GB2280606A (en) 1995-02-08
EP0490648B1 (en) 1995-12-06
DE4140858A1 (de) 1992-06-17
SK279813B6 (sk) 1999-04-13
IT1256282B (it) 1995-11-29
US5319097A (en) 1994-06-07
CN1105705C (zh) 2003-04-16
KR100207802B1 (ko) 1999-07-15
HK81397A (en) 1997-06-27
FI915826L (fi) 1992-03-31
CA2319308A1 (en) 1992-06-13

Similar Documents

Publication Publication Date Title
GR3018318T3 (en) Pharmaceutical agents.
DE69107059D1 (en) Sigma-delta-modulator.
AR244753A1 (es) Azocolorantes.
PH31205A (en) Pharmaceutical composition.
GR3025363T3 (en) Medicaments.
ZA919660B (en) Alpha-oxoacetamide derivatives.
ZA927562B (en) Medicament.
DE69111595D1 (en) Squarylium- und crokonyliumfarbstoffe.
DE69104185D1 (en) Luftreservoir.
DE69112211D1 (en) Luftreinigungsvorrichtung.
PH30977A (en) Hiv-inhibiting benzene-acetamide derivatives.
DE69106281D1 (en) Phenanthrenderivat.
OA09810A (en) Pharmaceutical composition.
DE69102644D1 (en) Demodulationsreferenzsignalquelle.
DE69114491D1 (en) Olefincopolymere.
DE69110012D1 (en) Linienerkennungsverfahren.
ZA918381B (en) Pharmaceutical compositions.
DE59100097D1 (en) Plungerzylinder.
GB9000241D0 (en) Pharmaceutical use
ZA939626B (en) Pharmaceutical compounds.
DE69100445D1 (en) Thiosulfatfixierloesungen.
ZA917789B (en) Pharmaceutical preparation.
EG19223A (en) Therapeutic agents.
ZA929916B (en) Therapeutic agents.
GB9027014D0 (en) Pharmaceutical agents